Dysautonomia (Autonomic Dysfunction) Market to Observe Stunning Growth During the Forecast Period (2022-32) | Key Players – Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics

Dysautonomia (Autonomic Dysfunction) Market to Observe Stunning Growth During the Forecast Period (2022-32) | Key Players - Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics
Delveinsight Business Research LLP
As per DelveInsight, the competitive landscape for the Dysautonomia (Autonomic Dysfunction) market is set to evolve immensely during the forecast period (2022-32), owing to the rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. Moreover, the increasing morbidity rate of Autonomic dysfunction and increasing awareness about available treatment options will also drive the therapeutics market growth.

DelveInsight’s “Dysautonomia (Autonomic Dysfunction) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dysautonomia (Autonomic Dysfunction) market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Dysautonomia (Autonomic Dysfunction) market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dysautonomia (Autonomic Dysfunction) Market

Dysautonomia (Autonomic Dysfunction): An Overview

Autonomic Dysfunction develops when the nerves of the ANS are damaged. This condition is called Autonomic Neuropathy or Dysautonomia. Autonomic dysfunction can range from mild to life-threatening. It can affect a part of the ANS or the entire ANS. Sometimes the conditions that cause problems are temporary and reversible. Others are chronic or long-term and may continue to worsen over time. Diabetes and Parkinson’s disease are two examples of chronic conditions that can lead to autonomic dysfunction.

Autonomic dysfunction can vary in symptoms and severity and often stem from different underlying causes. Certain types of autonomic dysfunction can be very sudden and severe, yet also reversible. Different types of autonomic dysfunction include: Postural orthostatic tachycardia syndrome (POTS), Neurocardiogenic syncope (NCS), Multiple system atrophy (MSA), Hereditary sensory and autonomic neuropathies (HSAN), Holmes-Adie syndrome (HAS), and other types of autonomic dysfunction can result from disease or damage to the body.

Dysautonomia (Autonomic Dysfunction) Market Key Facts

  • As per the study conducted by Christopher J Mathias et al., Autonomic Disease may be present in any age group; at birth in familial dysautonomia, in teenage years in vasovagal syncope, and between the ages of 30–50 years in familial amyloid polyneuropathy (FAP). Neurodegenerative disorders affecting the autonomic nervous system often occur after the age of 50 years.

  • As per the study conducted by José Javier Mendoza-Velásquez et al. 2019, Parkinson’s disease (PD) is the second-most-common neurodegenerative disease, affecting two to three percent of the population above 65 years of age. The prevalence of autonomic dysfunction in PD ranges between 50% and 70%. The most common dysautonomic symptoms in PD are constipation, urinary dysfunction, and orthostatic hypotension (OH).

Dysautonomia (Autonomic Dysfunction) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dysautonomia (Autonomic Dysfunction) market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Dysautonomia (Autonomic Dysfunction) market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Dysautonomia (Autonomic Dysfunction) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Dysautonomia (Autonomic Dysfunction) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dysautonomia (Autonomic Dysfunction) market or expected to get launched during the study period. The analysis covers the Dysautonomia (Autonomic Dysfunction) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dysautonomia (Autonomic Dysfunction) Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Dysautonomia (Autonomic Dysfunction) Market Will Evolve by 2032 @ 


Dysautonomia (Autonomic Dysfunction) Therapeutics Landscape:

The first goal of treating Autonomic Dysfunction is to manage the disease or condition damaging nerves. Many of the medications used to treat dysautonomia are considered off-label. The therapeutic agents used in the treatment of Autonomic Dysfunction include- Alpha-1 Agonists, Mineralocorticoids, Anticholinergic agents, Beta-adrenergic blockers, Phosphodiesterase inhibitors, Neuromuscular blocker agent, Anticholinergic agents, and Corticosteroids.

To redress the current issues and further improve the treatment scenario, several pharma companies are shifting their focus toward this indication to meet the needs of the current market. Pipeline drugs in clinical development are designed to address this unmet need in the Autonomic dysfunction treatment market.

The Leading Companies in the Dysautonomia (Autonomic Dysfunction) Market Include:

  • Celltex Therapeutics

  • Theravance Biopharma

  • PTC Therapeutics 

And many others.

Dysautonomia (Autonomic Dysfunction) Therapies Covered in the report include:

  • Mesenchymal stem cells

  • TD-9855

  • PTC258

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @ 


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Dysautonomia (Autonomic Dysfunction) Competitive Intelligence Analysis

4. Dysautonomia (Autonomic Dysfunction) Market Overview at a Glance

5. Dysautonomia (Autonomic Dysfunction) Disease Background and Overview

6. Dysautonomia (Autonomic Dysfunction) Patient Journey

7. Dysautonomia (Autonomic Dysfunction) Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Dysautonomia (Autonomic Dysfunction) Treatment Algorithm, Current Treatment, and Medical Practices

9. Dysautonomia (Autonomic Dysfunction) Unmet Needs

10. Key Endpoints of Dysautonomia (Autonomic Dysfunction) Treatment

11. Dysautonomia (Autonomic Dysfunction) Marketed Products

12. Dysautonomia (Autonomic Dysfunction) Emerging Drugs and Latest Therapeutic Advances

13. Dysautonomia (Autonomic Dysfunction) Seven Major Market Analysis

14. Attribute Analysis

15. Dysautonomia (Autonomic Dysfunction) Market Outlook (In US, EU5, and Japan)

16. Dysautonomia (Autonomic Dysfunction) Access and Reimbursement Overview

17. KOL Views on the Dysautonomia (Autonomic Dysfunction) Market

18. Dysautonomia (Autonomic Dysfunction) Market Drivers

19. Dysautonomia (Autonomic Dysfunction) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 


Other Trending Healthcare Reports By DelveInsight

Dysautonomia or Autonomic Dysfunction Pipeline Insights

“Dysautonomia/Autonomic Dysfunction Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Dysautonomia or Autonomic Dysfunction market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/